Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up - Should You Buy?

Key Points

• Shares gapped up pre-market, opening at $18.00 versus the prior close of $16.965 (about a 4.1% rise) on light volume of 5,663 shares.
• Barclays downgraded Hikma from "hold" to "strong sell" (Jan. 6); overall analyst coverage is mixed with one Buy and one Sell, producing an average "Hold" rating.
• The stock is trading below its 50‑day ($18.76) and 200‑day ($20.59) moving averages, while balance‑sheet metrics show moderate leverage (debt/equity 0.57) and modest liquidity (current ratio 1.82, quick ratio 1.06).

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $16.9650, but opened at $18.00. Hikma Pharmaceuticals shares last traded at $18.00, with a volume of 5,663 shares traded.

Analyst Upgrades and Downgrades

Separately, Barclays cut Hikma Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, January 6th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold".

Hikma Pharmaceuticals Stock Up 4.1%

The stock has a 50-day moving average of $18.76 and a two-hundred day moving average of $20.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.82 and a quick ratio of 1.06.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company's three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.